MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)

Ye GUO; Chaosu HU; Chenping ZHANG

doi:10.19401/j.cnki.1007-3639.2025.11.010

您当前的位置：

首页 >

文章列表页 >

MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)

Guideline and Consensus | 更新时间：2025-12-31

- MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)
- China Oncology Vol. 35, Issue 11, Pages: 1076-1089(2025)
- 作者机构：
  
  中国临床肿瘤学会头颈肿瘤专家委员会
- 作者简介：
  
  HU Chaosu E-mail: hucsu62@163.com;
  ZHANG Chenping E-mail: zhang.chenping@hotmail.com
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2025.11.010
  CLC： R739.91
- Received：15 September 2025，
  
  Revised：2025-11-04，
  
  Published：30 November 2025
- 稿件说明：
移动端阅览
Ye GUO, Chaosu HU, Chenping ZHANG. MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)[J]. China Oncology, 2025, 35(11): 1076-1089.
DOI：

Ye GUO, Chaosu HU, Chenping ZHANG. MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)[J]. China Oncology, 2025, 35(11): 1076-1089. DOI： 10.19401/j.cnki.1007-3639.2025.11.010.

摘要

约2/3的头颈部鳞状细胞癌患者就诊时处于局部晚期，即便采用多学科团队（multidisciplinary team，MDT）的诊疗模式，其治疗结局仍有待改进。免疫治疗已经成为复发转移性头颈部鳞状细胞癌的标准治疗，近年来在局部晚期特别是围手术期的临床研究中获得了初步成功，但在不同场景具体应用方面依然面临诸多问题。中国临床肿瘤学会头颈肿瘤专家委员会组织专家基于循证医学证据及临床实践探索，经过多轮讨论，最终形成14条共识意见。本共识全面涵盖局部晚期头颈部鳞状细胞癌免疫治疗的各种治疗场景，归纳如下：① 在全程治疗策略方面，对于拟接受根治性手术及辅助放化疗的局部晚期头颈部鳞状细胞癌患者，推荐采用新辅助免疫治疗、免疫治疗联合放化疗及辅助免疫治疗的全程治疗模式。② 在新辅助治疗阶段，对于需要进行新辅助免疫治疗的患者，建议选择免疫治疗联合化疗方案，疗程为2~3个周期；对于新辅助治疗后影像学评估显示肿瘤缓解且需要保留器官功能的非口腔癌患者，应采用根治性放疗。③ 免疫治疗联合放疗阶段目前尚存在争议，其最佳治疗方案和适用人群有待进一步临床研究探索。④ 在辅助免疫治疗阶段，对于具有高危因素的局部晚期头颈部鳞状细胞癌患者，术后推荐采用辅助放疗联合免疫治疗的综合方案，辅助免疫治疗的疗程为6~12个月。本共识将有利于指导局部晚期头颈部鳞状细胞癌免疫治疗的规范化应用，并且为下一步的临床研究奠定基础，力求提高国内局部晚期头颈部鳞状细胞癌免疫治疗的研究水平。本共识已在国际实践指南注册与透明化平台（Practice guideline REgistration for transPAREncy，PREPARE）上注册，注册号为PREPARE-2025CN1241。

Abstract

Approximately two-thirds of patients with head and neck squamous cell carcinoma present with locally advanced disease at the time of consultation. Even with the multidisciplinary team (MDT) diagnosis and treatment model

their treatment outcomes still need improvement. Immunotherapy has become the standard treatment for recurrent and metastatic head and neck squamous cell carcinoma. In recent years

it has achieved initial success in clinical studies on locally advanced diseases

especially in the perioperative period

but its application in other treatment fields still faces many problems. The Head and Neck Cancer Committee of Chinese Society of Clinical Oncology organized experts to form 14 consensus opinions through multiple rounds of discussions informed by evidence-based medical evidence and clinical practice. Thess consensus statements were finally formulated

comprehensively covering the entire management of immunotherapy for locally advanced head and neck squamous cell carcinoma

summarized as follows: ① Regarding the whole-course treatment strategy

for patients with locally advanced head and neck squamous cell carcinoma undergoing radical surgery followed by adjuvant chemoradiotherapy

a comprehensive treatment approach combining neoadjuvant immunotherapy

immunotherapy combined with chemoradiotherapy

and adjuvant immunotherapy is recommended. ② In the neoadjuvant treatment phase

for patients requiring neoadjuvant immunotherapy

the combination of immunotherapy with chemotherapy is recommended

with a course of 2-3 cycles. For non-oral cancer patients who achieve radiological tumor response after neoadjuvant treatment and require organ preservation

definitive radiotherapy should be administered. ③ The immunotherapy combined with radiotherapy phase remains controversial

and the optimal treatment regimen and patient selection criteria require further clinical investigation. ④ In the adjuvant immunotherapy phase

for locally advanced head and neck squamous cell carcinoma patients with high-risk factors

the combination of adjuvant radiotherapy with immunotherapy is recommended postoperatively

with a course of adjuvant immunotherapy ranging from 6 to 12 months. Corresponding recommendation levels for different treatment scenarios are obtained through voting. This consensus will help guide the standardized application of immunotherapy for locally advanced head and neck squamous cell carcinoma

lay the foundation for further clinical research

and strive to promote the research level of immunotherapy for locally advanced head and neck squamous cell carcinoma in China.This consensus has been registered on the Practice guideline REgistration for transPAREncy (PREPARE) platform

with the registration number PREPARE-2025CN1241.

关键词

Keywords

references

HAN B F , ZHENG R S , ZENG H M , et al . Cancer incidence and mortality in China, 2022 [J ] . J Natl Cancer Cent , 2024 , 4 ( 1 ): 47 - 53 .

中国临床肿瘤学会指南工作委员会组织 . 中国临床肿瘤学会(CSCO)头颈部肿瘤诊疗指南-2025[M ] . 北京 : 人民卫生出版社 , 2025 .

Guidelines Working Committee of Chinese Society of Clinical Oncology . Head and Neck Cancer Guidelines of Chinese Society of Clinical Oncology (CSCO) (2025 ed )[M ] . Beijing : People’s Medical Publishing House , 2025 .

MODY M D , ROCCO J W , YOM S S , et al . Head and neck cancer [J ] . Lancet , 2021 , 398 ( 10318 ): 2289 - 2299 . DOI: 10.1016/S0140-6736(21)01550-6 http://doi.org/10.1016/S0140-6736(21)01550-6

CHOW L Q M . Head and neck cancer [J ] . N Engl J Med , 2020 , 382 ( 1 ): 60 - 72 . DOI: 10.1056/NEJMra1715715 http://doi.org/10.1056/NEJMra1715715 http://www.nejm.org/doi/10.1056/NEJMra1715715 http://www.nejm.org/doi/10.1056/NEJMra1715715

BURTNESS B , HARRINGTON K J , GREIL R , et al . Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study [J ] . Lancet , 2019 , 394 ( 10212 ): 1915 - 1928 . DOI: S0140-6736(19)32591-7 http://doi.org/S0140-6736(19)32591-7

European Society for Medical Oncology . ESMO clinical practice guidelines-methodology manual. Version 2.3 [EB/OL ] . ( 2023-10-01 )[ 2025-08-15 ] . https://www.esmo.org/guidelines/esmo-guidelines-methodology. https://www.esmo.org/guidelines/esmo-guidelines-methodology https://www.esmo.org/guidelines/esmo-guidelines-methodology .

UPPALURI R , ZOLKIND P , LIN T , et al . Neoadjuvant pembrolizumab for resectable head and neck squamous cell carcinoma [J ] . N Engl J Med , 2025 , 393 ( 1 ): 37 - 50 . DOI: 10.1056/NEJMoa2415434 http://doi.org/10.1056/NEJMoa2415434 http://www.nejm.org/doi/10.1056/NEJMoa2415434 http://www.nejm.org/doi/10.1056/NEJMoa2415434

National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology: head and neck cancers. Version 5.2025 : Version 5.2025 [EB/OL ] .[ 2025-08-15 ] . https://www.nccn.org. https://www.nccn.org https://www.nccn.org

TOPALIAN S L , TAUBE J M , PARDOLL D M . Neoadjuvant checkpoint blockade for cancer immunotherapy [J ] . Science , 2020 , 367 ( 6477 ): eaax0182.

LI X , FANG Q G , DU W , et al . Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma [J ] . BMC Cancer , 2021 , 21 ( 1 ): 622 . DOI: 10.1186/s12885-021-08373-8 http://doi.org/10.1186/s12885-021-08373-8

WISE-DRAPER T M , GULATI S , PALACKDHARRY S , et al . Phase Ⅱ clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma [J ] . Clin Cancer Res , 2022 , 28 ( 7 ): 1345 - 1352 . DOI: 10.1158/1078-0432.CCR-21-3351 http://doi.org/10.1158/1078-0432.CCR-21-3351 https://aacrjournals.org/clincancerres/article/28/7/1345/682205/Phase-II-Clinical-Trial-of-Neoadjuvant-and https://aacrjournals.org/clincancerres/article/28/7/1345/682205/Phase-II-Clinical-Trial-of-Neoadjuvant-and

JU W T , XIA R H , ZHU D W , et al . A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma [J ] . Nat Commun , 2022 , 13 ( 1 ): 5378 . DOI: 10.1038/s41467-022-33080-8 http://doi.org/10.1038/s41467-022-33080-8

HUANG X T , LIU Q D , ZHONG G H , et al . Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): an open label, single-arm, phase Ⅰb clinical trial [J ] . J Exp Clin Cancer Res , 2022 , 41 ( 1 ): 300 . DOI: 10.1186/s13046-022-02510-2 http://doi.org/10.1186/s13046-022-02510-2

ZHANG Z J , WU B , PENG G , et al . Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: a single-arm phase 2 clinical trial [J ] . Clin Cancer Res , 2022 , 28 ( 15 ): 3268 - 3276 . DOI: 10.1158/1078-0432.CCR-22-0666 http://doi.org/10.1158/1078-0432.CCR-22-0666 https://aacrjournals.org/clincancerres/article/28/15/3268/707102/Neoadjuvant-Chemoimmunotherapy-for-the-Treatment https://aacrjournals.org/clincancerres/article/28/15/3268/707102/Neoadjuvant-Chemoimmunotherapy-for-the-Treatment

HUANG Y Y , SUN J J , LI J , et al . Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (illuminate trial) [J ] . Int J Surg , 2023 , 109 ( 8 ): 2220 - 2227 . DOI: 10.1097/JS9.0000000000000489 http://doi.org/10.1097/JS9.0000000000000489

WU W J , LIU Q , AN P G , et al . Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real-world retrospective study [J ] . Front Immunol , 2023 , 14 : 1282629 . DOI: 10.3389/fimmu.2023.1282629 http://doi.org/10.3389/fimmu.2023.1282629 https://www.frontiersin.org/articles/10.3389/fimmu.2023.1282629/full https://www.frontiersin.org/articles/10.3389/fimmu.2023.1282629/full

OU X M , ZHAI R P , WEI W J , et al . Induction toripalimab and chemotherapy for organ preservation in locally advanced laryngeal and hypopharyngeal cancer: a single-arm phase Ⅱ clinical trial [J ] . Clin Cancer Res , 2024 , 30 ( 2 ): 344 - 355 . DOI: 10.1158/1078-0432.CCR-23-2398 http://doi.org/10.1158/1078-0432.CCR-23-2398 https://aacrjournals.org/clincancerres/article/30/2/344/733191/Induction-Toripalimab-and-Chemotherapy-for-Organ https://aacrjournals.org/clincancerres/article/30/2/344/733191/Induction-Toripalimab-and-Chemotherapy-for-Organ

GONG H L , TIAN S , DING H , et al . Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase Ⅱ clinical trial [J ] . Nat Commun , 2024 , 15 ( 1 ): 5251 . DOI: 10.1038/s41467-024-49121-3 http://doi.org/10.1038/s41467-024-49121-3

WU D , LI Y , XU P F , et al . Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase Ⅱ trial [J ] . Nat Commun , 2024 , 15 ( 1 ): 2177 . DOI: 10.1038/s41467-024-46444-z http://doi.org/10.1038/s41467-024-46444-z

DUNN L , CRACCHIOLO J , HO A L , et al . Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC) [J ] . Ann Oncol , 2024 , 35: S619.

GUI L , XIE Z , ZHANG W , et al . Tislelizumab plus nab-paclitaxel and cisplatin as induction immunochemotherapy for organ preservation of locally advanced hypopharyngeal squamous cell carcinoma: a single-arm phase Ⅱ trial [J ] . ESMO Open , 2025 , 10 ( 8 ): 105505 . DOI: 10.1016/j.esmoop.2025.105505 http://doi.org/10.1016/j.esmoop.2025.105505 https://linkinghub.elsevier.com/retrieve/pii/S2059702925013742 https://linkinghub.elsevier.com/retrieve/pii/S2059702925013742

YANG K Y , ZHANG X M , ZHANG Z J , et al . REMATCH2201: a phase Ⅱ study on reducing surgical margins in HPV-negative advanced HNSCC with neoadjuvant PD-1 inhibitor and AP chemotherapy [J ] . J Clin Oncol , 2025, 43 ( 16_suppl ): 6011.

WANG H L , WANG X D , LI Y W , et al . Neoadjuvant PD-1 inhibitor combined with Nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NCT05522985): a randomized, controlled, open label, phase Ⅱ clinical trial [J ] . J Clin Oncol , 2025 , 43 ( 16_suppl ): 6018.

YAN S D , ZHANG X , LI F J , et al . Neoadjuvant sintilimab and chemotherapy followed by transoral surgery for HPV-positive resectable oropharyngeal cancer: a single-arm, two-centre, phase 2 trial [J ] . eClinicalMedicine , 2025 , 86 : 103393 . DOI: 10.1016/j.eclinm.2025.103393 http://doi.org/10.1016/j.eclinm.2025.103393 https://linkinghub.elsevier.com/retrieve/pii/S2589537025003256 https://linkinghub.elsevier.com/retrieve/pii/S2589537025003256

LIU Z G , WANG D , LI G J , et al . Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase Ⅱ single-arm trial [J ] . Nat Commun , 2025 , 16 : 4608 . DOI: 10.1038/s41467-025-59865-1 http://doi.org/10.1038/s41467-025-59865-1

XIANG Z Z , WEI X Y , ZHANG Z Y , et al . Efficacy, safety and single-cell analysis of neoadjuvant immunochemotherapy in locally advanced oral squamous cell carcinoma: a phase Ⅱ trial [J ] . Nat Commun , 2025 , 16 ( 1 ): 3968 . DOI: 10.1038/s41467-025-59004-w http://doi.org/10.1038/s41467-025-59004-w

LI B W , XIE S L , HAN J J , et al . Neoadjuvant chemoimmunotherapy in resectable locally advanced oral squamous cell carcinoma: a single-center retrospective cohort study [J ] . Int J Surg , 2025 , 111 ( 1 ): 781 - 790 . DOI: 10.1097/JS9.0000000000001891 http://doi.org/10.1097/JS9.0000000000001891 https://journals.lww.com/10.1097/JS9.0000000000001891 https://journals.lww.com/10.1097/JS9.0000000000001891

WU W J , AN P G , LIU Q , et al . Neoadjuvant chemoimmunotherapy brings superior quality of life of patients with locally advanced oral or oropharyngeal cancer: a propensity score-matched analysis [J ] . Oral Oncol , 2025 , 162 : 107218 . DOI: 10.1016/j.oraloncology.2025.107218 http://doi.org/10.1016/j.oraloncology.2025.107218 https://linkinghub.elsevier.com/retrieve/pii/S1368837525000478 https://linkinghub.elsevier.com/retrieve/pii/S1368837525000478

HEINHUIS K M , ROS W , KOK M , et al . Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors [J ] . Ann Oncol , 2019 , 30 ( 2 ): 219 - 235 . DOI: S0923-7534(19)31044-0 http://doi.org/S0923-7534(19)31044-0

CAO L M , YU Y F , LI Z Z , et al . Neoadjuvant chemoimmunotherapy for resectable head and neck squamous cell carcinoma: systematic review and meta-analysis [J ] . Ann Surg Oncol , 2025 , 32 ( 7 ): 5206 - 5217 . DOI: 10.1245/s10434-025-17195-y http://doi.org/10.1245/s10434-025-17195-y

WIDJAJA W , NG I , SHANNON N , et al . Neoadjuvant immunotherapy in resectable HNSCC: an updated systematic review and meta-analysis [J ] . Ann Surg Oncol , 2025 , 32 ( 4 ): 2713 - 2724 . DOI: 10.1245/s10434-024-16587-w http://doi.org/10.1245/s10434-024-16587-w

CHEN S S , YANG Y F , WANG R , et al . Neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy had a higher ORR than mono-immunotherapy in untreated HNSCC: Meta-analysis [J ] . Oral Oncol , 2023 , 145 : 106479 . DOI: 10.1016/j.oraloncology.2023.106479 http://doi.org/10.1016/j.oraloncology.2023.106479 https://linkinghub.elsevier.com/retrieve/pii/S1368837523001756 https://linkinghub.elsevier.com/retrieve/pii/S1368837523001756

WU W J , WANG L , ZHANG T , et al . Neoadjuvant tislelizumab plus chemotherapy followed by salvage surgery and adjuvant tislelizumab for recurrent head and neck squamous cell carcinoma after radiotherapy: a single-arm, phase Ⅱ trial [J ] . J Clin Oncol , 2024 , 42 ( 16_suppl ): 6070.

ROSENBERG A J , JULOORI A , JELINEK M J , et al . Neoadjuvant nivolumab plus chemotherapy followed by response-stratified chemoradiation therapy in HPV-negative head and neck cancer: the DEPEND phase 2 nonrandomized clinical trial [J ] . JAMA Oncol , 2025 , 11 ( 5 ): 492 - 501 . DOI: 10.1001/jamaoncol.2025.0081 http://doi.org/10.1001/jamaoncol.2025.0081

WANG Y F , LIU Z G , YUAN H F , et al . The reciprocity between radiotherapy and cancer immunotherapy [J ] . Clin Cancer Res , 2019 , 25 ( 6 ): 1709 - 1717 . DOI: 10.1158/1078-0432.CCR-18-2581 http://doi.org/10.1158/1078-0432.CCR-18-2581

LEE N Y , FERRIS R L , PSYRRI A , et al . Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial [J ] . Lancet Oncol , 2021 , 22 ( 4 ): 450 - 462 . DOI: 10.1016/S1470-2045(20)30737-3 http://doi.org/10.1016/S1470-2045(20)30737-3

MACHIELS J P , TAO Y G , LICITRA L , et al . Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial [J ] . Lancet Oncol , 2024 , 25 ( 5 ): 572 - 587 . DOI: 10.1016/S1470-2045(24)00100-1 http://doi.org/10.1016/S1470-2045(24)00100-1 https://linkinghub.elsevier.com/retrieve/pii/S1470204524001001 https://linkinghub.elsevier.com/retrieve/pii/S1470204524001001

TAO Y , AUPERIN A , SUN X , et al . 854MO Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): final analysis of randomized phase Ⅲ GORTEC 2017-01 REACH trial [J ] . Ann Oncol , 2024 , 35: S616.

TAO Y , BIAU J , SUN X S , et al . Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase Ⅱ trial [J ] . Ann Oncol , 2023, 34 ( 1 ): 101 - 110 . DOI: 10.1016/j.annonc.2022.10.006 http://doi.org/10.1016/j.annonc.2022.10.006 https://linkinghub.elsevier.com/retrieve/pii/S0923753422041977 https://linkinghub.elsevier.com/retrieve/pii/S0923753422041977

MELL L K , TORRES-SAAVEDRA P A , WONG S J , et al . Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial [J ] . Lancet Oncol , 2024 , 25 ( 12 ): 1576 - 1588 . DOI: 10.1016/S1470-2045(24)00507-2 http://doi.org/10.1016/S1470-2045(24)00507-2

MOUNTZIOS G , REMON J , HENDRIKS L E L , et al . Immune-checkpoint inhibition for resectable non-small cell lung cancer -opportunities and challenges [J ] . Nat Rev Clin Oncol , 2023 , 20 ( 10 ): 664 - 677 . DOI: 10.1038/s41571-023-00794-7 http://doi.org/10.1038/s41571-023-00794-7

BOURHIS J , AUPERIN A , BOREL C , et al . ( NIVOPOSTOP GORTEC 2018-01): a phase Ⅲ randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse [J ] . J Clin Oncol , 2025 , 43 ( 17_suppl ): LBA2.

HADDAD R , FAYETTE J , TEIXEIRA M , et al . Atezolizumab in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomized clinical trial [J ] . JAMA , 2025 , 333 ( 18 ): 1599 - 1607 . DOI: 10.1001/jama.2025.1483 http://doi.org/10.1001/jama.2025.1483

LEDDON J L , GULATI S , HAQUE S , et al . Phase Ⅱ trial of adjuvant nivolumab following salvage resection in patients with recurrent squamous cell carcinoma of the head and neck [J ] . Clin Cancer Res , 2022 , 28 ( 16 ): 3464 - 3472 . DOI: 10.1158/1078-0432.CCR-21-4554 http://doi.org/10.1158/1078-0432.CCR-21-4554 https://aacrjournals.org/clincancerres/article/28/16/3464/707395/Phase-II-Trial-of-Adjuvant-Nivolumab-Following https://aacrjournals.org/clincancerres/article/28/16/3464/707395/Phase-II-Trial-of-Adjuvant-Nivolumab-Following

GUERLAIN J , COZIC N , DASTE A , et al . Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (HNSCC): phase Ⅱ trial evaluating the efficacy and the toxicity of nivolumab (ADJORL1) [J ] . Ann Oncol , 2023 , 34: S557.

PEARSON A T , SEIWERT T Y , COHEN R B , et al . A randomized, double-blind, placebo-controlled phase Ⅱ study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: the PATHWay study [J ] . J Clin Oncol , 2024 , 42 ( 16_suppl ): 6008.

Views

235

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Advances and future perspectives of neoadjuvant immunotherapy in colorectal cancer

Application progress of oncolytic virus combined with immunotherapy in the treatment of malignant tumors

Chinese expert consensus on clinical application of recombinant oncolytic adenovirus in the treatment of malignant tumors

Current status and future directions of immunotherapy for advanced non-small cell lung cancer

Advances in immunotherapy for metastatic renal cancer

Related Author

Yuyang ZHANG

Qian LIU

Yingyun LIANG

Jianhua CHEN

Expert Committee on Immunotherapy of Chinese Society of Clinical Oncology

Professional Committee on Cancer Biotherapy of Shanghai Anticancer Association

Chunxia SU

Caicun ZHOU

Related Institution

Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Shanghai Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University

复旦大学附属肿瘤医院泌尿外科，复旦大学上海医学院肿瘤学系

AI问答

⁰